Clora

In the first quarter of this year, the biotech industry saw substantial layoffs, impacting 57 companies and thousands of employees. This matches the number of companies affected in Q1 2023. Layoffs have been a critical topic of discussion at major events like the JPM Healthcare Conference and BIO-IT World. Companies are navigating financial constraints and restructuring efforts, which have led to significant workforce reductions across the sector. More from Fierce Biotech here: https://ow.ly/JMhP50RT5q0 Despite these challenges, the need for innovation and progress remains strong for newly founded and existing biotechs. To sustain momentum and continue advancing development, companies must find flexible and efficient solutions. Clora's platform connects you with top-tier, on-demand consultants to keep programs on track without high fixed costs. By leveraging our network, you can adapt to industry changes while ensuring your critical work continues seamlessly. What are your thoughts on the current biotech environment? Comment below! #Clora #biotech #lifesciences #consulting #healthcare

Clora CEO Rahul Chaturvedi hosts an inspiring new episode of the Biotech2050 podcast featuring Robert Ang, CEO of Vor Bio. Dive into an engaging discussion on next-gen cancer therapies, including Vor’s shielded CD33-deleted stem cell transplants and CAR-T cell therapies for AML and MDS. Robert also shares his unique approach to building passionate and impactful teams. Listen using the link below. #Clora #biotech #podcast #cancer #stemcelltransplant

Meet with us at BIO 2024 in San Diego! This global event brings together leaders from the biopharma industry to explore the latest innovations and trends. Send us a message to book a meeting with our CEO Rahul Chaturvedi to explore how Clora can optimize your organization's operating model to ensure you have the right talent at the right time to set your programs up for success. #BIO2024 #biotech #pharma #innovation #biopharma

Court decisions have dismissed recent lawsuits by Bristol Myers Squibb and Johnson & Johnson against the U.S. government's Inflation Reduction Act's (IRA) drug pricing provisions. This follows intense industry discussions, notably around the IRA's impact on investments and prioritization of drug modalities, with moves underway to balance negotiation periods for biologics and small molecules. Companies like Relay Therapeutics have already adjusted their strategies, citing the IRA for pausing commercialization of rare disease oncology therapy RLY-4008. Read more in this article by Fierce Pharma about how this could reshape the future of healthcare innovations: https://ow.ly/UUag50RzENI #pharma #drugdevelopment #healthcare #biopharma

Our CEO Rahul Chaturvedi recently hosted Vik Bajaj of Foresite Labs on the Biotech2050 podcast. A trailblazer at the nexus of tech and life sciences, Vik helped incubate Xaira Therapeutics, an integrated biotech driving advances in AI to transform how we treat disease. Rahul and Vik explore the evolving interplay of capital investments, technology and biotech, and discuss key insights and future trends that are shaping healthcare delivery and beyond. Tune in using the link below. #Clora #biotech #podcast #tech #lifesciences #healthcare

At Clora, we’re dedicated to fostering innovation and collaboration within the biotech community. That’s why we’re thrilled to share highlights from the recent Bio-IT World Conference where our Founder & CEO, Rahul Chaturvedi moderated an insightful panel discussion on “Strategies for Biotech Success: Insights on Raising Capital from CEOs and VCs.” In an ever-evolving landscape, navigating capital acquisition is paramount for biotech companies. Rahul led the discussion, delving into recent shifts in funding trends, anticipating market expectations, and providing invaluable and actionable insights on selecting the right investors amidst competitive markets. Missed the discussion? Reach out / comment below ⬇ to learn more about how Clora is driving innovation and collaboration in the biotech landscape. 🌟 Many thanks to the amazing panelists - Kimberly Nearing from BVCF Management Ltd, Trevor Perry from Selas Ventures, Jami Rubin from Boundless Bio and ARCH Venture Partners, Chris Shibutani MD MBA from Goldman Sachs, and Scott Megaffin from Adiso Therapeutics. 🌟 #Biotech #BioITWorld #Clora #VC

As a biotech startup scales, there are inflection points where it's important to tactically replace some of your generalists with specialists. In this #Biotech2050Rewind, Harlan Robins discusses this and other challenges he faced transitioning from an early stage founder to the successful leader of a much larger company. If you're looking for experts to grow your company to the next level, Clora can help. Click here to learn more: http://clora.info/3VQIEJB

In the Biotech, the right talent doesn’t just fill a role—it pioneers the future of life sciences. That’s why we’ve introduced a new feature on Clora for HR leaders and Hiring Managers in Biotech: tailor your screening process with AI-driven questions, crafted for the distinct challenges of biotech. Find the right talent with AI screening questions by joining Clora https://clora.info/3VQIEJB We’re here to streamline the on-demand talent hiring process, so that you can discover the trailblazers of tomorrow fast. #BiotechHR #InnovativeHiring #HRtech #BiotechInnovation #AIforHR #TalentDiscovery

Check out this past Biotech2050 episode where Troy Wilson (President and CEO of Kura Oncology, Inc.) and Rahul Chaturvedi (CEO of Clora) delve into the world of precision cancer medicine and shed light on effective team and board member recruitment strategies. Biotech2050 is a weekly podcast hosted by Rahul focusing on the future of Biotech. Catch up on this episode below! #Clora #Biotech #Recruitment